US Patent Issued to Praxis Precision Medicines on June 10 for "3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4triazolo[4,3-Alphapyrazine as an ion channel modulator" (American, Canadian Inventors)

ALEXANDRIA, Va., June 18 -- United States Patent no. 12,325,711, issued on June 10, was assigned to Praxis Precision Medicines Inc. (Boston).

"3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4triazolo[4,3-Alphapyrazine as an ion channel modulator" was invented by Andrew Mark Griffin (Montreal), Brian Edward Marron (Ada, Mich.) and Gabriel Martinez Botella (Wayland, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to, in part, a compound having the structure:or a pharmaceutically acceptable salt thereof, useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for ex...